Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh